- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Ambulatory BP Monitoring: Time for an Expanded Role in Office Practice?
Twenty-four-hour ambulatory blood pressure (BP) monitoringis a more accurate predictor of stroke and myocardialinfarction than office BP measurement, according tothe results of the recent Office Versus Ambulatory BloodPressure Study. This prospective trial followed 1963 patientswith treated hypertension for 5 years.
Twenty-four-hour ambulatory blood pressure (BP) monitoringis a more accurate predictor of stroke and myocardialinfarction than office BP measurement, according tothe results of the recent Office Versus Ambulatory BloodPressure Study. This prospective trial followed 1963 patientswith treated hypertension for 5 years.Key findings. Study participants with a mean 24-hoursystolic BP of 135 mm Hg or higher were almost twice aslikely to have a cardiovascular event.1 Those with a mean24-hour BP lower than 130/80 mm Hg had the same riskof cardiovascular events as normotensive persons.Guidelines for optimal use of ambulatory BP monitoringin clinical practice are outlined in the Algorithm.
References:
REFERENCES:
1.
Clement DL, De Buyzere ML, De Bacquer DA, et al, for the Office VersusAmbulatory Pressure Study Investigators. Prognostic value of ambulatory bloodpressurerecordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-2415.
2.
White WB. Ambulatory blood-pressure monitoring in clinical practice. N EnglJ Med. 2003;348:2377-2378.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
